20 recruiting, 18 unknown, 12 not yet recruiting, 11 completed. 17 Phase 2, 16 Not applicable, 8 Early Phase 1, 8 Phase 3, 5 Phase 1.
Follow Immunoglobulin G4-Related Disease: new trials by email Literature Review of Immunoglobulin G4-Related Disease trials Research Report on Immunoglobulin G4-Related Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RD Inebilizumab - Immunoglobulin G4-related Disease | Phase 2 | Not yet recruiting | Amgen | 15 | 2026-10-31 | 2026-08-27 |
| Nebulized UC-EVs for Recurrent or Refractory IMIDs With Lung Involvement nebulized human umbilical cord mesenchymal stromal cell-derived extracellular vesicles - IgG4 Related Disease, Systemic Sclerosis (SSc) | Early Phase 1 | Not yet recruiting | Qiubai Li | 18 | 2026-10-14 | 2026-09-08 |
| BCT301 in Treating Refractory/Recurrent IgG4-related Disease BCT301 Cell Injection - IgG4-related Disease | Not applicable | Not yet recruiting | Peking University Third Hospital | 6 | 2026-10-01 | 2026-08-31 |
| A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Autoimmune Diseases LVIVO-TaVec400 product - Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE), Relapsed/Refractory IgG4-Related Disease (r/r IgG4-RD) | Early Phase 1 | Withdrawn | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2026-09-23 | 2026-10-02 | |
| Tripterygium Wilfordii Plus Prednisone for Active IgG4-Related Disease Prednisone, tripterygium wilfordii - IgG4 Related Disease | Phase 2 | Not yet recruiting | Peking Union Medical College Hospital | 74 | 2026-09-01 | 2026-10-16 |
| Efficacy and Safety of Lenalidomide in Patients With IgG4-Related Disease Lenalidomide, Placebo - Immunoglobulin G4-Related Disease | Phase 3 | Not yet recruiting | Chinese PLA General Hospital | 146 | 2026-08-01 | 2026-07-22 |
| A Study of IMM0306 in IgG4-Related Disease IMM0306, Placebo - IgG4-Related Disease | Phase 2 / Phase 3 | Not yet recruiting | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | 125 | 2026-07-01 | 2026-06-02 |
| A Study to Evaluate MTM-H-001 Injection in Adult Patients With B-Cell-Related Autoimmune Diseases MTM-H-001 Injection - Systemic Lupus Erthematosus (SLE), Lupus Nephritis (LN) | Not applicable | Not yet recruiting | Beijing GoBroad Hospital | 75 | 2026-06-01 | 2026-05-18 |
| Validation of the Odesa Criteria 2026 for Autoimmune Pancreatitis No intervention (observational study) - Autoimmune Pancreatitis, IgG4-Related Diseases | Recruiting | Military Medical Clinical Center of the Southern Region, Ukraine | 82 | 2026-05-01 | 2026-05-28 | |
| Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease ACE1831, Lymphodepleting chemotherapy - IgG4 Related Disease | Phase 1 / Phase 2 | Recruiting | Acepodia Biotech, Inc. | 34 | 2026-01-01 | 2026-10-02 |
| An Exploratory Clinical Study on the Safety and Efficacy of CD19/BCMA CAR-NK in the Treatment of Relapsed and Refractory IgG4-related Disease CD19/BCMA CAR NK - IgG4 Related Disease | Early Phase 1 | Not yet recruiting | Changhai Hospital | 18 | 2025-12-30 | 2025-12-23 |
| A Study of Efgartigimod in Patients With IgG4-Related Disease Efgartigimod - IgG4-related Disease | Phase 2 | Active not recruiting | Stanford University | 5 | 2025-11-12 | 2026-07-23 |
| the Safety and Efficacy of Targeted BCMA In Vivo LV Injection for Recurrent or Refractory Autoimmune Diseases V001-BCMA - Recurrent or Refractory Systemic Lupus Erythematosus, Recurrent or Refractory IgG4 Related Diseases | Early Phase 1 | Active not recruiting | Tongji Hospital | 45 | 2025-11-04 | 2026-09-17 |
| A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease Rilzabrutinib, Placebo, Glucocorticoid - Immunoglobulin G4 Related Disease | Phase 3 | Recruiting | Sanofi | 124 | 2025-09-26 | 2026-10-20 |
| The Investigators Will Evaluate the Diagnostic Performance of [18F]-AlF-FAPI-74 PET/CT in Inflammatory Disorders and Compare it With the Current Gold Standard for Inflammation, FDG PET/CT, in Three Patient Cohort: Patients Presenting With Fever of Unknown Origin, IgG4-RD and AxSpA. [18F]AlF-FAPI-74 PET/CT - Fever of Unknown Origin, IgG4 Related Disease | Phase 2 / Phase 3 | Recruiting | Universitaire Ziekenhuizen KU Leuven | 140 | 2025-09-17 | 2026-04-17 |
| Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related Disease Anti-BCMA-CD19 CAR-T cells - IgG4 Related Disease, B-cell Mediated Autoimmune Disorders | Phase 2 | Recruiting | Chinese PLA General Hospital | 9 | 2025-09-05 | 2025-09-03 |
| A Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the Treatment of Active IgG4-related Disease 5mg lenalidomide, 10mg lenalidomide, Prednisone monotherapy - IgG4 Related Disease | Phase 2 / Phase 3 | Recruiting | Peking Union Medical College Hospital | 198 | 2025-07-07 | 2025-12-30 |
| A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases YTS109 cell - Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc) | Phase 1 | Recruiting | China Immunotech (Beijing) Biotechnology Co., Ltd. | 12 | 2025-05-19 | 2026-10-21 |
| A Study on the Effect of MRD Detected by FAPI PET / CT on the Recurrence of IgG4-RD 68Ga-FAPI PET / CT - IgG4-Related Diseases | Not applicable | Recruiting | Luo Yaping | 46 | 2025-05-10 | 2025-08-05 |
| UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases universal allogeneic anti-CD19/BCMA CAR T-cells - Systemic Lupus Erythematosus, Autoimmune Hemolytic Anemia | Phase 1 | Not yet recruiting | Changzhou No.2 People's Hospital | 18 | 2025-05-01 | 2025-05-18 |
Showing 20 of 69. Sign in to see all of them.
Autoimmune Diseases (9) · Lupus Erythematosus, Systemic (8) · Myositis (8) · Recurrence (7) · Scleroderma, Systemic (7) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (6) · Arthritis, Rheumatoid (5) · Lupus Nephritis (4) · Sjogren's Syndrome (3) · Antiphospholipid Syndrome (2) · Autoimmune Pancreatitis (2) · Behcet Syndrome (2) · Myasthenia Gravis (2) · Retroperitoneal Fibrosis (2)
Immune System Diseases (69) · Autoimmune Diseases (60) · Pathological Conditions, Signs and Symptoms (17) · Skin and Connective Tissue Diseases (16) · Pathologic Processes (15) · Connective Tissue Diseases (13) · Disease Attributes (12) · Skin Diseases (12) · Nervous System Diseases (11) · Musculoskeletal Diseases (10) · Cardiovascular Diseases (9) · Neuromuscular Diseases (9) · Vascular Diseases (9) · Muscular Diseases (8) · Skin Diseases, Vascular (8)
Prednisone (10) · Mycophenolic Acid (4) · Glucocorticoids (3) · Leflunomide (3) · Lenalidomide (3) · Prednisolone (3) · Hematologic Tests (2) · inebilizumab (2) · tofacitinib (2) · 68Ga-FAPI (1) · Abatacept (1) · Acetaminophen (1) · Adrenal Cortex Hormones (1) · Blood Specimen Collection (1) · Cyclophosphamide (1)
Peking Union Medical College Hospital (14) · Chinese PLA General Hospital (3) · Meir Medical Center (3) · Tongji Hospital (3) · Wen Zhang (3) · Amgen (2) · Assistance Publique Hopitaux De Marseille (2) · Changhai Hospital (2) · Mayo Clinic (2) · Peking University People's Hospital (2) · Peking University Third Hospital (2) · Acepodia Biotech, Inc. (1) · Beijing Friendship Hospital (1) · Beijing GoBroad Hospital (1) · Changzhou No.2 People's Hospital (1)
China (40) · United States (14) · Spain (7) · France (6) · Israel (5) · Italy (5) · Japan (5) · Argentina (4) · Canada (4) · Germany (4) · Poland (4) · Netherlands (3) · Turkey (Türkiye) (3) · United Kingdom (3) · Belgium (2)
Wen Zhang, MD (8) · Fengchun Zhang (2) · Adrian Gadano, MD (1) · Eduardo Jorge Premoli, MD (1) · Fang Li, MD (1) · Gao Jie, doctor (1) · Hernan Garcia Rivello, MD (1) · Ignatio Sanz, MD (1) · Jaap M van Laar, Prof. dr. (1) · Javier Pollan, MD (1) · Jian Zhu (1) · Jian Zhu, MD, PhD (1) · Jing Pan, Ph.D (1)
PMID 38216319, PMID 18757334, PMID 24764034, PMID 25481539, PMID 25616460, PMID 28183334, PMID 30124952, PMID 31491234, PMID 32113839, PMID 32234383, PMID 32733900, PMID 35333600, PMID 37792260, PMID 38251576, PMID 38602546, PMID 38643278, PMID 39541094, PMID 39672025, PMID 39915014, PMID 39956699, PMID 41786624, PMID 41840328, PMID 42129009, PMID 42233621, PMID 42731845
2025 (2), 2023 (1), R37AI049660 (1), UM1AI144298 (1)